Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine® ER for chronic pruritus (itch). 


The Company is in Phase 3 clinical development for uremic pruritus and prurigo nodularis.

Trevi Therapeutics Announces Positive Results from Phase 2 Trial in Prurigo Nodularis
Oral Nalbuphine ER trial achieved positive results of reduced itch intensity and other supporting efficacy endpoints in prurigo nodularis patients
Trevi Therapeutics to Present Two Posters at the National Kidney Foundation Spring 2016 Meeting
Authors available to discuss clinical studies results regarding Nalbuphine ER for hemodialysis patients with uremic pruritus